http://www.unboundmedicine.com/medline/ebm/research/Imodium_AdvancedUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/18026190/full_citation/A_phase_I_dose_escalation_study_of_BIBW_2992_an_irreversible_dual_inhibitor_of_epidermal_growth_factor_receptor_1__EGFR__and_2__HER2__tyrosine_kinase_in_a_2_week_on_2_week_off_schedule_in_patients_with_advanced_solid_tumours_Eskens FA, Mom CH, Planting AS, et al. 
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. [JOURNAL ARTICLE]
Br J Cancer 2007 Nov 20.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/17634493/full_citation/Phase_I_and_pharmacokinetic_study_of_the_oral_farnesyltransferase_inhibitor_lonafarnib_administered_twice_daily_to_pediatric_patients_with_advanced_central_nervous_system_tumors_using_a_modified_continuous_reassessment_method:_a_Pediatric_Brain_Tumor_Consortium_Study_Kieran MW, Packer RJ, Onar A, et al. 
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. [Journal Article, Research Support, N.I.H., Extramural]
J Clin Oncol 2007 Jul 20; 25(21):3137-43.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/16847088/full_citation/Prevention_and_Self_Treatment_of_Traveler's_Diarrhea_Diemert DJ 
Prevention and Self-Treatment of Traveler's Diarrhea. [Journal Article]
Clin Microbiol Rev 2006 Jul; 19(3):583-94.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/16020959/full_citation/Prospective_double_blind_placebo_controlled_multicenter_randomized_phase_III_study_with_orally_administered_budesonide_for_prevention_of_irinotecan__CPT_11__induced_diarrhea_in_patients_with_advanced_colorectal_cancer_Karthaus M, Ballo H, Abenhardt W, et al. 
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
Oncology 2005; 68(4-6):326-32.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/16003560/full_citation/A_pilot_study_on_the_safety_of_combining_chrysin_a_non_absorbable_inducer_of_UGT1A1_and_irinotecan__CPT_11__to_treat_metastatic_colorectal_cancer_Tobin PJ, Beale P, Noney L, et al. 
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. [Clinical Trial, Journal Article]
Cancer Chemother Pharmacol 2006 Feb; 57(3):309-16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15569974/full_citation/A_phase_I_trial_of_perifosine__NSC_639966__on_a_loading_dose/maintenance_dose_schedule_in_patients_with_advanced_cancer_Van Ummersen L, Binger K, Volkman J, et al. 
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
Clin Cancer Res 2004 Nov 15; 10(22):7450-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15514383/full_citation/Phase_II_study_of_activated_charcoal_to_prevent_irinotecan_induced_diarrhea_Michael M, Brittain M, Nagai J, et al. 
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
J Clin Oncol 2004 Nov 1; 22(21):4410-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15288289/full_citation/Phase_II_studies_of_BBR3464_a_novel_tri_nuclear_platinum_complex_in_patients_with_gastric_or_gastro_oesophageal_adenocarcinoma_Jodrell DI, Evans TR, Steward W, et al. 
Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
Eur J Cancer 2004 Aug; 40(12):1872-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15254061/full_citation/Recommended_guidelines_for_the_treatment_of_cancer_treatment_induced_diarrhea_Benson AB, Ajani JA, Catalano RB, et al. 
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. [Guideline, Journal Article, Practice Guideline]
J Clin Oncol 2004 Jul 15; 22(14):2918-26.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/15160318/full_citation/Resolution_of_refractory_chemotherapy_induced_diarrhea__CID__with_octreotide_long_acting_formulation_in_cancer_patients:_11_case_studies_Rosenoff S 
Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. [Case Reports, Journal Article]
Support Care Cancer 2004 Aug; 12(8):561-70.
Abstract | Full Citation | Publisher Full Text | Find Related Articles